Valneva ( (VALN) ) has shared an announcement.
On February 28, 2025, Valneva SE announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending the authorization of a label extension for their chikungunya vaccine, IXCHIQ®, to include adolescents aged 12 and older. This recommendation, based on positive Phase 3 data showing strong immune responses in adolescents, marks a significant step towards broader accessibility of the vaccine in the EU and potentially other regions. The expansion aligns with Valneva’s strategy to increase vaccine access globally, including partnerships to supply the vaccine in low- and middle-income countries.
More about Valneva
Valneva SE is a specialty vaccine company focused on developing, manufacturing, and commercializing prophylactic vaccines for infectious diseases with unmet medical needs. The company applies a highly specialized and targeted approach across multiple vaccine modalities, offering first-, best-, or only-in-class vaccine solutions. Valneva markets three proprietary travel vaccines, including the world’s first chikungunya vaccine, and collaborates with partners like Pfizer on advanced vaccine candidates for diseases such as Lyme disease and Zika virus.
YTD Price Performance: 50.85%
Average Trading Volume: 64,954
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $600.8M
See more insights into VALN stock on TipRanks’ Stock Analysis page.